maralixibat; lopixibat (Livmarli)
Jump to navigation
Jump to search
Indications
- treatment of cholestatic pruritus in patients with Alagille syndrome >= 1 year
Dosage
- 380 ug/kg once daily, taken 30 minutes before 1st meal of day
- starting dose: 190 ug/kg orally once daily
- increase to 380 ug/kg once daily after one week, as tolerated
Oral solution: 9.5 mg of maralixibat per mL.
Adverse effects
- most common (> 5%)
- diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver function test abnormalities, gastrointestinal bleeding, bone fractures
Laboratory
- baseline & periodic liver function tests
Mechanism of action
- ileal bile acid transporter (IBAT) inhibitor
References
- ↑ Medscape: maralixibat (Rx) https://reference.medscape.com/drug/livmarli-maralixibat-4000208
- ↑ Highlights of preascribing information maralixibat (Livmarli) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214662s000lbl.pdf